vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and i-80 Gold Corp. (IAUX). Click either name above to swap in a different company.
i-80 Gold Corp. is the larger business by last-quarter revenue ($21.3M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -401.9%, a 401.1% gap on every dollar of revenue. CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-39.2M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
i-80 Gold Corp is a mineral exploration and development firm focused on gold and silver asset operations in Nevada, US. It advances high-potential mining projects, using responsible extraction practices to deliver precious metals to global industrial and investment markets.
CTMX vs IAUX — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $21.3M |
| Net Profit | $-154.0K | $-85.6M |
| Gross Margin | — | 22.0% |
| Operating Margin | -6.9% | -291.6% |
| Net Margin | -0.8% | -401.9% |
| Revenue YoY | -25.7% | — |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $32.0M | ||
| Q2 25 | $18.7M | $27.8M | ||
| Q1 25 | $50.9M | $14.0M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $11.5M | ||
| Q2 24 | $25.1M | $7.2M | ||
| Q1 24 | $41.5M | — |
| Q4 25 | — | $-85.6M | ||
| Q3 25 | — | $-41.9M | ||
| Q2 25 | $-154.0K | $-30.2M | ||
| Q1 25 | $23.5M | $-41.2M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-43.1M | ||
| Q2 24 | $-6.5M | $-41.0M | ||
| Q1 24 | $13.8M | — |
| Q4 25 | — | 22.0% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -42.7% | ||
| Q2 24 | — | -171.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | -291.6% | ||
| Q3 25 | — | -86.7% | ||
| Q2 25 | -6.9% | -67.4% | ||
| Q1 25 | 44.4% | -112.3% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | -210.0% | ||
| Q2 24 | -33.7% | -435.2% | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | -401.9% | ||
| Q3 25 | — | -130.8% | ||
| Q2 25 | -0.8% | -108.5% | ||
| Q1 25 | 46.2% | -293.3% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -374.5% | ||
| Q2 24 | -26.0% | -570.8% | ||
| Q1 24 | 33.3% | — |
| Q4 25 | — | $-0.10 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $63.2M |
| Total DebtLower is stronger | — | $174.7M |
| Stockholders' EquityBook value | $119.9M | $346.8M |
| Total Assets | $175.1M | $703.4M |
| Debt / EquityLower = less leverage | — | 0.50× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.2M | ||
| Q3 25 | — | $102.9M | ||
| Q2 25 | $49.0M | $133.7M | ||
| Q1 25 | $47.6M | $13.5M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $21.8M | ||
| Q2 24 | $43.2M | $47.8M | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $174.7M | ||
| Q3 25 | — | $175.9M | ||
| Q2 25 | — | $175.8M | ||
| Q1 25 | — | $197.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $346.8M | ||
| Q3 25 | — | $423.0M | ||
| Q2 25 | $119.9M | $463.5M | ||
| Q1 25 | $25.0M | $318.0M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $346.9M | ||
| Q2 24 | $-31.2M | $377.2M | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | — | $703.4M | ||
| Q3 25 | — | $756.2M | ||
| Q2 25 | $175.1M | $782.9M | ||
| Q1 25 | $98.5M | $659.0M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | — | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | — |
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-34.3M |
| Free Cash FlowOCF − Capex | $-15.8M | $-39.2M |
| FCF MarginFCF / Revenue | -84.6% | -184.3% |
| Capex IntensityCapex / Revenue | 0.1% | 23.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-93.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-34.3M | ||
| Q3 25 | — | $-15.2M | ||
| Q2 25 | $-15.8M | $-11.3M | ||
| Q1 25 | $-21.0M | $-22.7M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | $-23.5M | ||
| Q2 24 | $-19.5M | $-24.6M | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | — | $-39.2M | ||
| Q3 25 | — | $-18.5M | ||
| Q2 25 | $-15.8M | $-12.4M | ||
| Q1 25 | $-21.2M | $-23.1M | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | $-23.8M | ||
| Q2 24 | $-19.6M | $-25.1M | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | -184.3% | ||
| Q3 25 | — | -57.8% | ||
| Q2 25 | -84.6% | -44.7% | ||
| Q1 25 | -41.6% | -164.1% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | -206.7% | ||
| Q2 24 | -78.2% | -349.1% | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | 0.1% | 3.9% | ||
| Q1 25 | 0.2% | 2.5% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | 2.5% | ||
| Q2 24 | 0.4% | 7.3% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
IAUX
| Granite Creek Mining Company | $20.3M | 95% |
| Ruby Hill Mining Company LLC | $991.0K | 5% |
| Lone Tree Minning Company | $3.0K | 0% |
